A phase II multi-center study of triple therapy with paclitaxel, s-1 and cisplatin in patients with advanced gastric cancer

Oncology

Volumn 80, Issue 1-2, 2011, Pages 76-83

  Iwase, H ^a   Shimada, M ^a   Tsuzuki, T ^a   Ina, K ^b   Sugihara, M ^c   Haruta, J ^d   Shinoda, M ^e   Kumada, T ^f   Goto, H ^g  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b Nagoya Memorial Hospital   (Japan)

^c Meitetsu Hospital   (Japan)

^d JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^e TOYOTA MEMORIAL HOSPITAL   (Japan)

^f OGAKI MUNICIPAL HOSPITAL   (Japan)

^g NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Combination therapy; Gastric cancer; Paclitaxel; Phase II; S 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATININE; DEXAMETHASONE; DIPHENHYDRAMINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HEMOGLOBIN; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CORTICOSTEROID THERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; EPIPHORA; ESOPHAGUS METASTASIS; FATIGUE; FEMALE; HUMAN; INFECTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYOSITIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMACH CANCER; STOMACH CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TEAR FLOW; THROMBOCYTOPENIA; URTICARIA;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEUTROPENIA; OXONIC ACID; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 79958052494     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328746     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics. 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H, Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163-168. (Pubitemid 27112884)
3. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrevate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267. (Pubitemid 27020582)
4. Wills J: The treatment of advanced gastric cancer. Semin Oncol 1996; 23: 397-406.
5. Kim NK, Parrk YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-3818. (Pubitemid 23172955)
6. Findly M, Cunningham D, Norman A, Mansi J, Nicooson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609-616. (Pubitemid 24283097)
7. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2009.
8. Shirasaka T, Shimamoto Y, Ohshino H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil delivative (S1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulation. Anticancer Drugs 1996; 7: 548-557. (Pubitemid 26276346)
9. Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000; 58: 191-197. (Pubitemid 30189900)
10. Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, Tsukuma H, Tsujitani T, Furukawa H, Taguchi T: Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology 2008; 74: 37-41. (Pubitemid 351915008)
11. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Toda S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006; 12: 3042-3047.
12. Uedo N, Narahara H, Ishihara R, Takiuchi H, Goto M, Fujitani K, Hirao M, Tsujinaka T, Imano M, Furukawa H, Tsukuma H, Taguchi T, Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Phase II study of combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG002). Oncology 2007; 73: 65-71. (Pubitemid 351465602)
13. Iwase H, Shimada M, Tsuzuki T, Horiuchi Y, Kumada S, Haruta J, Yamaguchi T, Ugihara M, Ina K, Kusugami K, Goto H: Phase II multicentric trial of S-1 combined 24 h-infusion of cisplatin in patients with advanced gastric cancer. Anticancer Res 2005; 25: 1297-1302.
14. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kibayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone to first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
15. Iwase H, Shimada M, Tsuzuki T, Okeya M, Kobayashi K, Hibio Y, Watanabe H: Phase I study of S-1 administration and a 24 hourinfusion of cisplatin plus paclitaxel in patients with advanced gastric cancer. Anticancer Res 2006; 26: 1605-1610.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosteroma AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
17. Japanese Research Society for Gastric Cancer: Response Assessment of Chemotherapy for Gastric Carcinoma. Japanese Classification of Gastric Carcinoma. 1st Engl ed. Tokyo, Kanehara, 1995, pp 90-104.
18. Yamao T, Schimada Y, Shirao K, Ohtsu A, Ikeda N, Hyodo I, Saito H, Iwase H, Tsuji Y, Tamura T, Yamamoto S, Yoshida S: Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascots: a report from the gastrointestinal oncology study group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol 2004; 34: 316-322. (Pubitemid 43118050)
19. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W: Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47. (Pubitemid 30179675)
20. Ohtsu A, Shimada Y, Shirao K, Boku N, Hydo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yashida S: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21: 54-59.
21. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomized phase 3 study. Lancet Oncol 2009; 10: 1063-1069.
22. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunonva V, Vynnychenko I, Garin A, Lang I, Falcon S: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusion fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J Clin Oncol 2010; 28: 1547-1553.
23. Van Cutsen E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as the first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997. (Pubitemid 46631401)
24. Rosati G, Ferrara D, Manzione L: New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol 2009; 14: 2689-2692.
25. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Taguchi T: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitive reactions. Ann Oncol 2001; 12: 1133-1137. (Pubitemid 32834495)
26. Yamaguchi K, Tada M, Horikoshi N. Otani T, Takiuchi H, Saitoh S, Kanamaru R, Kasai Y, Koizumi W, Sakata Y, Taguchi T: Phase II study of paclitaxel with a 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002; 5: 90-95. (Pubitemid 34832243)
27. Sakamoto J: A new paradigm of chemotherapy for gastric cancer: speeding up, and more clinical trials to catch up. Gastric Cancer 2002; 5: 55-57. (Pubitemid 34832237)
28. Murad A, Petroianu A, Guimaraes RC, Aragao BC, Cagral LOM, Scalabrini-Neto AO: Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer. Am J Clin Oncol 1999; 22: 580-586. (Pubitemid 30266056)
29. Nukatsuka M, Fujioka A, Nakagawa F, Oshima H, Kitazato K, Uchida J, Sugimoto Y, Nagayama S, Fukushima M: Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. Int J Oncol 2004; 25: 1531-1536.
30. Vanhoefer U, Harstrick A, Wike H, Schleucher N, Walles H, Schröder J, Seeber S: Schedule dependent antagonism of paclitaxel and cisplatin in human gastric cancer ovarian carcinoma cell lines in vitro. Eur J Cancer 1995; 31A:92-97.
31. Kim YH, Shin SW, Kim BS, Kim JH, Kim JG, Mok YJ, Kim CS, Rhyu HS, Hyun JH, Kim JS: Paclitaxel, 5-fluorouracil and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85: 295-301. (Pubitemid 29051282)
32. De Jongh FE, de Wit R, Verweij J, Sparreboom A, van den Bent MJ, Stoter G, van der Burg MEL: Dose-dense cisplatin/paclitaxel. A well tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur J Cancer 2002; 38: 2005-2013.
33. Polee MB, Verweij J, Siersema PD, Tilanus HW, Splinter TAW, Stoter G, Van der Gaast A: Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. Eur J Cancer 2002; 38: 1495-1500. (Pubitemid 34756402)
34. Jacobs C, Bertino JR, Goffinet DR, Fee WE, Goode RL: 24-hour infusion of cis-platinum in head and neck cancers. Cancer 1978; 42: 2135-2140. (Pubitemid 9125866)